Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Hypertension. 2001;38:404-411

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sanada, S.
Right arrow Articles by Hori, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanada, S.
Right arrow Articles by Hori, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ENALAPRIL MALEATE
*LOSARTAN POTASSIUM

(Hypertension. 2001;38:404.)
© 2001 American Heart Association, Inc.

Scientific Contributions

Differential Subcellular Actions of ACE Inhibitors and AT1 Receptor Antagonists on Cardiac Remodeling Induced by Chronic Inhibition of NO Synthesis in Rats

Shoji Sanada; Masafumi Kitakaze; Koichi Node; Seiji Takashima; Akiko Ogai; Hiroshi Asanuma; Yasuhiko Sakata; Masanori Asakura; Hisakazu Ogita; Yulin Liao; Tomi Fukushima; Junko Yamada; Tetsuo Minamino; Tsunehiko Kuzuya; Masatsugu Hori

Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan.

Correspondence to Masafumi Kitakaze, MD, PhD, Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, 565-0871 Osaka, Japan. E-mail kitakaze{at}medone.med.osaka-u.ac.jp

Abstract—— Chronic inhibition of NO synthesis induces cardiac hypertrophy independent of systemic blood pressure (SBP) by increasing protein synthesis in vivo. We examined whether ACE inhibitors (ACEIs) enalapril and temocapril and angiotensin II type-I receptor antagonists (angiotensin receptor blockers [ARBs]) losartan and CS-866 can block cardiac hypertrophy and whether changes in activation of 70-kDa S6 kinase (p70S6K) or extracellular signal–regulated protein kinase (ERK) are involved. The following 13 groups were studied: untreated Wistar-Kyoto rats and rats treated with NO synthase inhibitor N{omega}-nitro-L-arginine methyl ester (L-NAME), D-NAME (the inactive isomer of L-NAME), L-NAME plus hydralazine, L-NAME plus enalapril (3 mg · kg-1 · d-1) or temocapril (1 or 10 mg · kg-1 · d-1), L-NAME plus losartan (10 mg · kg-1 · d-1) or CS-866 (1 or 10 mg · kg-1 · d-1), L-NAME plus temocapril-CS866 in combination (1 or 10 mg · kg-1 · d-1), and L-NAME plus rapamycin (0.5 mg · kg-1 · d-1). After 8 weeks of each experiment, ratios of coronary wall to lumen (wall/lumen) and left ventricular weight to body weight (LVW/BW) were quantified. L-NAME increased SBP, wall/lumen, and LVW/BW compared with that of control. ACEIs, ARBs, and hydralazine equally canceled the increase in SBP induced by L-NAME. However, ACEIs and ARBs equally (but not hydralazine) attenuated increase in wall/lumen and LVW/BW induced by L-NAME. The L-NAME group showed both p70S6K and ERK activation in myocardium (2.2-fold and 1.8-fold versus control, respectively). ACEIs inactivated p70S6K and ARBs inactivated ERK in myocardium, but hydralazine did not change activation of either kinase. Thus, ACEIs and ARBs modulate different intracellular signaling pathways, inhibiting p70S6K or ERK, respectively, to elicit equal reduction of cardiac hypertrophy induced by chronic inhibition of NO synthesis in vivo.


Key Words: remodeling • angiotensin-converting enzyme inhibitor • receptors, angiotensin • kinase




This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
J. Yatabe, H. Sanada, M. S. Yatabe, S. Hashimoto, M. Yoneda, R. A. Felder, P. A. Jose, and T. Watanabe
Angiotensin II type 1 receptor blocker attenuates the activation of ERK and NADPH oxidase by mechanical strain in mesangial cells in the absence of angiotensin II
Am J Physiol Renal Physiol, May 1, 2009; 296(5): F1052 - F1060.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
N. Sharma, I. C. Okere, M. K. Duda, D. J. Chess, K. M. O'Shea, and W. C. Stanley
Potential impact of carbohydrate and fat intake on pathological left ventricular hypertrophy
Cardiovasc Res, January 15, 2007; 73(2): 257 - 268.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
T.-M. Lee, M.-S. Lin, T.-F. Chou, and N.-C. Chang
Additive effects of combined blockade of AT1 receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats
Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1281 - H1289.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
D. Bell, Y.-Y. Zhao, E. J. Kelso, E. M. McHenry, L. M. Rush, V. M. Lamont, D. P. Nicholls, and B. J. McDermott
Upregulation of adrenomedullin and its receptor components during cardiomyocyte hypertrophy induced by chronic inhibition of nitric oxide synthesis in rats
Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H904 - H914.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
L. W. Hu, L. A. Benvenuti, E. A. Liberti, M. S. Carneiro-Ramos, and M. L. M. Barreto-Chaves
Thyroxine-induced cardiac hypertrophy: influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2003; 285(6): R1473 - R1480.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
S. Sanada, K. Node, T. Minamino, S. Takashima, A. Ogai, H. Asanuma, H. Ogita, Y. Liao, M. Asakura, J. Kim, et al.
Long-Acting Ca2+ Blockers Prevent Myocardial Remodeling Induced by Chronic NO Inhibition in Rats
Hypertension, April 1, 2003; 41(4): 963 - 967.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
Y. Nakamura, M. Yoshiyama, T. Omura, K. Yoshida, Y. Izumi, K. Takeuchi, S. Kim, H. Iwao, and J. Yoshikawa
Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction
Cardiovasc Res, January 1, 2003; 57(1): 48 - 54.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
O. Suda, M. Tsutsui, T. Morishita, A. Tanimoto, M. Horiuchi, H. Tasaki, P. L. Huang, Y. Sasaguri, N. Yanagihara, and Y. Nakashima
Long-Term Treatment With N{omega}-Nitro-L-Arginine Methyl Ester Causes Arteriosclerotic Coronary Lesions in Endothelial Nitric Oxide Synthase-Deficient Mice
Circulation, September 24, 2002; 106(13): 1729 - 1735.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. Sanada, K. Node, H. Asanuma, H. Ogita, S. Takashima, T. Minamino, M. Asakura, Y. Liao, A. Ogai, J. Kim, et al.
Opening of the adenosine triphosphate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide synthesis: Role of 70-kDa S6 kinase and extracellular signal-regulated kinase
J. Am. Coll. Cardiol., September 4, 2002; 40(5): 991 - 997.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
D Lang
Cardiac hypertrophy and oxidative stress: a leap of faith or stark reality?
Heart, April 1, 2002; 87(4): 316 - 317.
[Full Text] [PDF]


Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.